Isolation of genes altered by suppression of fibronectin type III domain containing protein 3A (FNDC3A) expression in MDA-MB-231 cells
Breast cancer is divided into several subtypes, and breast cancer that does not have estrogen receptor, progesterone receptor, or HER2 receptor is called triple negative breast cancer (TNBC). TNBC is difficult to treat because there is no therapeutic target, and it is known to have an extremely poor prognosis. FNDC3A is a protein that belongs to the FNDC family, and breast cancers with high expression have a poor prognosis. To evaluate the effect of FNDC3A on the malignant progression of TNBC, siRNA targeting FNDC3A was introduced into MDA-MB-231 cells. RNA was prepared from the cells 48 hours after transfection.